PDCD1 and neoplasm: The most commonly used are monoclonal antibodies, among others, blocking PD-1 molecules, present on the surface of T lymphocytes and PD-L1 molecules, found on the surface of tumor cells, and on the surface of immune cells, infiltrating the tumor microenvironment.